Literature DB >> 23253002

Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.

N K Loh1, M Lucas, S Fernandez, D Prentice.   

Abstract

A previously healthy 20-year-old man presented with adult Still disease (ASD). He developed life-threatening macrophage activation syndrome (MAS), which was refractory to standard immunosuppression but responded dramatically to the IL-1 receptor antagonist anakinra. Subsequent immunological investigations included assessment of the perforin expression of natural killer (NK) cells and CD8+ T cells, which confirmed MAS.
© 2012 The Authors; Internal Medicine Journal © 2012 Royal Australasian College of Physicians.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23253002     DOI： 10.1111/imj.12002

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


  16 in total

1.  Cross talk between neuroregulatory molecule and monocyte: nerve growth factor activates the inflammasome.

Authors:  Ananya Datta-Mitra; Smriti Kundu-Raychaudhuri; Anupam Mitra; Siba P Raychaudhuri
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

Review 2.  Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review.

Authors:  Mayan Gilboa; Gil Bornstein; Ilan Ben-Zvi; Chagai Grossman
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

3.  Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome*.

Authors:  Dennis W Simon; Rajesh Aneja; Joseph A Carcillo; E Scott Halstead
Journal:  Pediatr Crit Care Med       Date:  2014-06       Impact factor: 3.624

Review 4.  Autoinflammatory disease in the lung.

Authors:  Thomas Scambler; Jonathan Holbrook; Sinisa Savic; Michael F McDermott; Daniel Peckham
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

Review 5.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

6.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Authors:  Bita Shakoory; Joseph A Carcillo; W Winn Chatham; Richard L Amdur; Huaqing Zhao; Charles A Dinarello; Randall Q Cron; Steven M Opal
Journal:  Crit Care Med       Date:  2016-02       Impact factor: 7.598

Review 7.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 8.  The 'cytokine storm': molecular mechanisms and therapeutic prospects.

Authors:  Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Trends Immunol       Date:  2021-07-01       Impact factor: 19.709

Review 9.  Ebola Virus Disease has Features of Hemophagocytic Lymphohistiocytosis Syndrome.

Authors:  Andre J A M van der Ven; Mihai G Netea; Jos W M van der Meer; Quirijn de Mast
Journal:  Front Med (Lausanne)       Date:  2015-02-04

10.  Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review.

Authors:  Eri Watanabe; Hitoshi Sugawara; Takeshi Yamashita; Akira Ishii; Aya Oda; Chihiro Terai
Journal:  Case Rep Med       Date:  2016-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.